Dosing Schedule Allows Patients an Infusion-Free Week Between Cycles

28-day dosing cycles continue until disease progression or unacceptable toxicity 2*

nab-pac=nab-paclitaxel.
*Based on dosing schedule from IMpassion130. Visualization of vials is illustrative and does not represent actual vial usage.

 

  • For each 28-day cycle, TECENTRIQ is administered on Days 1 and 15, and nab-pac 100 mg/m2 is administered on Days 1, 8, and 15
    • On Days 1 and 15, TECENTRIQ should be administered first, followed by nab-pac
  • Administer the initial infusion of TECENTRIQ over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes
  • Do not administer TECENTRIQ as an IV push or bolus
  • Do not co-administer other drugs through the same IV line
  • TECENTRIQ and nab-pac may be discontinued for toxicity independently of each other
  • See also the Prescribing Information for nab-pac prior to initiation

840-mg single-dose vial now approved for TECENTRIQ

Dosage modifications from the TECENTRIQ Prescribing Information 2

Adverse reaction Severity of adverse reaction Dosage modifications
Pneumonitis Grade 2 Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 3 or 4 Permanently discontinue
Hepatitis AST or ALT >3 and ≤8 times ULN or total bilirubin >1.5 and ≤3 times ULN
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
AST or ALT >8 times ULN or total bilirubin >3 times ULN
Permanently discontinue
Colitis or diarrhea Grade 2 or 3
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4
Permanently discontinue
Endocrinopathies§ Grade 2, 3, or 4
Withhold dose until grade 1 or resolved and clinically stable on hormone replacement therapy
Other immune-mediated adverse reactions involving a major organ Grade 3 Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4 Permanently discontinue
Infections Grade 3 or 4 Withhold dose until grade 1 or resolved
Infusion-related reactions Grade 1 or 2 Interrupt or slow the rate of infusion
Grade 3 or 4 Permanently discontinue
Persistent grade 2 or 3 adverse reaction (excluding endocrinopathies) Grade 2 or 3 adverse reaction that does not recover to grade 0 or 1 within 12 weeks after last TECENTRIQ dose
Permanently discontinue
Inability to taper corticosteroid Inability to reduce to less than or equal to prednisone 10 mg per day (or equivalent) within 12 weeks after last TECENTRIQ dose
Permanently discontinue
Recurrent grade 3 or 4 adverse reaction Recurrent grade 3 or 4 (severe or life-threatening) adverse reaction
Permanently discontinue


ALT=alanine aminotransferase; AR=adverse reaction; AST=aspartate aminotransferase; IV=intravenous; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; ULN=upper limit of normal.
Consult the nab-pac Prescribing Information for dosage modifications and AR management.
NCI CTCAE v4.0.
§Including, but not limited to, hypophysitis, adrenal insufficiency, hyperthyroidism, and type 1 diabetes mellitus.